Eight non-splenectomized patients with corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) were treated with low-dose vincristine (1 mg/week up to a total dose of 4 mg). Complete remission was achieved in 2 cases and partial remission in 3. Bleeding stopped in one patient who failed to remit. No statistical relationship was found between the response to vincristine and the duration of the disease or the corticosteroid-therapy. Side effects were only observed in one patient. By comparing these results with those reported in the literature, it can be inferred that low-dose vincristine may be useful in the management of corticosteroid-refractory ITP.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426022 | PMC |
http://dx.doi.org/10.1136/pgmj.56.660.711 | DOI Listing |
Biomol Ther (Seoul)
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Curr Neurol Neurosci Rep
November 2024
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, 875 Blake Wilbur, MC 6510, Stanford, Palo Alto, CA, 94305, USA.
Exp Oncol
October 2024
Division of Pediatric Hematology/Oncology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Zhonghua Er Ke Za Zhi
October 2024
Department of Hematology & Oncology, Children's Hospital Affiliated to Shandong University(Jinan Children's Hospital), Jinan 250022, China.
Biol Pharm Bull
September 2024
Laboratory of Host Defense, Department of Pharma-Science, Teikyo University.
Cancer chemotherapy increases the risk of thrombosis; however, the mechanisms underlying this thrombosis are not completely understood. Plasminogen activator inhibitor (PAI)-1 is a key molecule in the fibrinolytic system that inhibits tissue plasminogen activator and urokinase, which converts plasminogen into plasmin; therefore, excess PAI-1 increases the risk of thrombosis. In this study, we investigated whether temporary treatment of the human luminal A-type breast cancer cell line MCF-7 with antitumor drugs clinically used for breast cancer therapy promotes PAI-1 production.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!